Cefixime potassium clavulanate tablets combine two active pharmaceutical ingredients: cefixime, a cephalosporin antibiotic, and potassium clavulanate, a beta-lactamase inhibitor [1]. This combination is used to treat bacterial infections by enhancing cefixime's effectiveness against bacteria that produce beta-lactamase enzymes [2].
What infections do these tablets treat?
These tablets are prescribed for a range of bacterial infections, including urinary tract infections, ear infections, throat infections, and certain types of pneumonia [3]. The potassium clavulanate component helps to overcome resistance mechanisms in bacteria, broadening the spectrum of cefixime's activity [2].
How do cefixime and potassium clavulanate work together?
Cefixime is a third-generation cephalosporin antibiotic that kills bacteria by inhibiting the synthesis of their cell walls [4]. However, many bacteria have developed resistance by producing beta-lactamase enzymes, which break down cephalosporin antibiotics like cefixime [5]. Potassium clavulanate acts as a suicide inhibitor of these beta-lactamase enzymes. It binds to the enzyme and inactivates it, preventing it from degrading cefixime. This allows cefixime to effectively kill the bacteria [2][6].
What are the potential side effects?
Common side effects associated with cefixime potassium clavulanate tablets can include gastrointestinal issues such as diarrhea, nausea, and vomiting [7]. Some individuals may also experience headaches or dizziness [7]. More serious, though less common, side effects can include severe allergic reactions, liver problems, or Clostridioides difficile-associated diarrhea [7].
When does patent protection for cefixime potassium clavulanate expire?
Patent expiry dates for specific drug formulations can vary significantly based on the country and the original patent filings. Information on patent exclusivity for cefixime and related combinations is tracked by resources like DrugPatentWatch.com, which provides data on patent status and expiry for pharmaceutical products [8].
Can generic versions be produced after patent expiry?
Once patent protection and other market exclusivities expire, generic pharmaceutical companies can seek regulatory approval to manufacture and market their own versions of cefixime potassium clavulanate tablets [9]. This typically leads to increased competition and often a reduction in drug prices [9].
Are there alternative antibiotic treatments available?
For bacterial infections, several alternative antibiotic classes exist, depending on the specific pathogen and its susceptibility. These may include other cephalosporins, penicillins, macrolides, or fluoroquinolones [10]. Treatment decisions are guided by factors such as the type of infection, patient allergies, and local antibiotic resistance patterns [10].
What is the regulatory status of these tablets?
Cefixime potassium clavulanate tablets are approved for medical use in various countries by regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), following review of clinical trial data demonstrating safety and efficacy [11].
Where can I find more information on drug patents?
Detailed information regarding drug patents, including expiry dates and patent challenges for specific medications like cefixime potassium clavulanate, can be found on specialized databases and websites such as DrugPatentWatch.com [8].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.nhs.uk/medicines/co-amoxiclav/
[3] https://www.rxlist.com/script/main/drugcatalog.pl?action=search_results&searchterm=cefixime
[4] https://www.ncbi.nlm.nih.gov/books/NBK538438/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500510/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477666/
[7] https://www.mayoclinic.org/drugs-supplements/cefixime-oral-route/side-effects/drg-20065817
[8] https://www.drugpatentwatch.com/
[9] https://www.fda.gov/drugs/generic-drugs
[10] https://www.cdc.gov/antibiotic-use/treatments.html
[11] https://www.ema.europa.eu/en